UroGen Pharma Ltd
Company Profile
Business description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Contact
400 Alexander Park Drive
4th Floor
PrincetonNJ08540
USAT: +1 646 768-9780
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
253
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.20 | 1.30 | -0.01% |
| CAC 40 | 7,886.51 | 10.42 | -0.13% |
| DAX 40 | 23,626.37 | 122.49 | -0.52% |
| Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
| FTSE 100 | 9,252.88 | 24.15 | -0.26% |
| HKSE | 26,438.51 | 8.05 | -0.03% |
| NASDAQ | 22,348.75 | 207.64 | 0.94% |
| Nikkei 225 | 44,902.27 | 134.15 | 0.30% |
| NZX 50 Index | 13,234.89 | 26.58 | 0.20% |
| S&P 500 | 6,615.28 | 30.99 | 0.47% |
| S&P/ASX 200 | 8,877.70 | 3.00 | -0.03% |
| SSE Composite Index | 3,861.86 | 1.36 | 0.04% |